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Introduction {#embr201948885-sec-0001}
============

Glycosylation is an abundant post‐translational modification of both intracellular and extracellular proteins [1](#embr201948885-bib-0001){ref-type="ref"}. The majority of glycans are classified as N‐linked chains, where the carbohydrate moiety is attached to asparagine residues, or O‐linked chains, most commonly linked to a serine or threonine. N‐linked glycosylation is initiated by the oligosaccharyltransferase complex with only two paralogs of the catalytic subunit, whereas O‐glycan initiation is more complex. There are several types of O‐linked glycosylation, but among the most diverse is the mucin or GalNAc type (hereafter referred to as O‐glycosylation). O‐glycosylation is initiated by 20 evolutionarily conserved polypeptide GalNAc‐transferases (GalNAc‐Ts), which add GalNAc residues to serine and threonine amino acids (Fig [1](#embr201948885-fig-0001){ref-type="fig"}A). Each of the GalNAc‐Ts is differentially expressed in various tissues and has both distinct and overlapping peptide substrate specificities [2](#embr201948885-bib-0002){ref-type="ref"}, [3](#embr201948885-bib-0003){ref-type="ref"}, [4](#embr201948885-bib-0004){ref-type="ref"}, [5](#embr201948885-bib-0005){ref-type="ref"}, [6](#embr201948885-bib-0006){ref-type="ref"}, [7](#embr201948885-bib-0007){ref-type="ref"}, [8](#embr201948885-bib-0008){ref-type="ref"}, [9](#embr201948885-bib-0009){ref-type="ref"}, [10](#embr201948885-bib-0010){ref-type="ref"}, [11](#embr201948885-bib-0011){ref-type="ref"}, [12](#embr201948885-bib-0012){ref-type="ref"}. Thus, the repertoire of GalNAc‐Ts expressed in a given cell determines the subset and O‐glycosite pattern of glycosylated proteins [13](#embr201948885-bib-0013){ref-type="ref"}. Substantial efforts have been made to characterize and predict the substrate specificities of GalNAc‐Ts *in vitro,* but understanding of the *in vivo* specificities of the individual GalNAc‐Ts or their biological functions is limited [13](#embr201948885-bib-0013){ref-type="ref"}, [14](#embr201948885-bib-0014){ref-type="ref"}, [15](#embr201948885-bib-0015){ref-type="ref"}. This lack of insight prevents an understanding of how site‐specific O‐linked glycosylation affects diseases, such as metabolic disorders, cardiovascular disease, and various malignancies, that have been associated with GalNAc‐Ts through genome‐wide association studies and other linkage studies [16](#embr201948885-bib-0016){ref-type="ref"}, [17](#embr201948885-bib-0017){ref-type="ref"}, [18](#embr201948885-bib-0018){ref-type="ref"}, [19](#embr201948885-bib-0019){ref-type="ref"}, [20](#embr201948885-bib-0020){ref-type="ref"}, [21](#embr201948885-bib-0021){ref-type="ref"}, [22](#embr201948885-bib-0022){ref-type="ref"}, [23](#embr201948885-bib-0023){ref-type="ref"}, [24](#embr201948885-bib-0024){ref-type="ref"}, [25](#embr201948885-bib-0025){ref-type="ref"}, [26](#embr201948885-bib-0026){ref-type="ref"}. Therefore, it is imperative that we establish how O‐glycosylation at specific sites in proteins affects protein function.

![Phenotypic characterization\
O‐GalNAc‐type O‐glycosylation pathway. Biosynthesis of core 1‐type structures is shown.Strategy for generation and characterization of *GALNT* isoform knock outs in HaCaT keratinocytes.Expression of *GALNT* isoforms in primary keratinocytes and HaCaT cell line. The scatter plot depicts individual RPKM values of 2 biological replicates.Expression of GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3 in human skin (upper panel) and HaCaT keratinocyte organoids (lower panel). Frozen human skin or HaCaT keratinocyte organotypic skin models were stained using antibodies for the GalNAc‐T isoforms. Scale bar---25 μm.Phenotypic characterization of organotypic models made with HaCaT WT or *GALNT1/2/3* KO keratinocytes. IHC of tissue sections stained for differentiation marker keratin 10 (upper panel) or proliferation marker Ki67 (lower panel). Scale bar---50 μm. Red arrows---flattened cells; red asterisks---K10‐negative region in suprabasal/granular layers; purple asterisks---pyknotic nuclei; and green asterisks--increase in Ki67‐positive cells.Quantification of epidermal thickness of skin organotypic models. Epidermal thickness was measured in 5 distinct images (4 positions/image) of 4 clones of *GALNT* isoform KO or WT (4 different tissues) and is presented as averages +SD. Due to high ZFN KO phenotypic inter‐clonal variation and to exclude off target effects, 5 clones of ZFN and 3 clones of CRISPR KO (each targeted by a different gRNA) were used for *GALNT3* KO. ANOVA followed by Dunnet\'s multiple comparison test was used to compare mean epidermal thicknesses of different KOs to WT. \**P* ≤ 0.05; \*\*\*\**P* ≤ 0.0001.Quantification of keratin 10‐negative area in skin organotypic tissue sections. Keratin 10‐negative area was measured in 5 distinct images of 4 clones of *GALNT* isoform KO or WT (4 different tissues) and is presented as averages +SD. Due to high ZFN KO phenotypic inter‐clonal variation and to exclude off target effects, 5 clones of ZFN and 3 clones of CRISPR KO (each targeted by a different gRNA) were used for *GALNT3* KO. ANOVA followed by Dunnet\'s multiple comparison test was used to compare mean areas of different KOs to WT. \*\*\*\**P* ≤ 0.0001.RNAseq expression data of select differentiation markers, expressed in spinous and granular layers of the epidermis (cartoon). Expression data are presented as log~2~(average KO/average WT). Significantly changed transcripts, identified in R analysis, are marked with asterisks.](EMBR-21-e48885-g002){#embr201948885-fig-0001}

We and others recently developed new strategies for identifying specific sites on proteins that undergo O‐glycosylation in different cell types and tissues [27](#embr201948885-bib-0027){ref-type="ref"}, [28](#embr201948885-bib-0028){ref-type="ref"}, [29](#embr201948885-bib-0029){ref-type="ref"}, [30](#embr201948885-bib-0030){ref-type="ref"}, [31](#embr201948885-bib-0031){ref-type="ref"}. Characterization of the O‐glycoproteomic landscape in isolated human cells and multiple human cell lines suggests that more than 80% of all proteins that traffic through the secretory pathway are O‐glycoproteins [28](#embr201948885-bib-0028){ref-type="ref"}, [30](#embr201948885-bib-0030){ref-type="ref"}. Probing the non‐redundant contributions of individual GalNAc‐Ts in cells lacking specific enzymes [32](#embr201948885-bib-0032){ref-type="ref"}, [33](#embr201948885-bib-0033){ref-type="ref"}, [34](#embr201948885-bib-0034){ref-type="ref"} has revealed broad substrate specificities for some of the individual isoforms and very restricted specificities for others [33](#embr201948885-bib-0033){ref-type="ref"}, [34](#embr201948885-bib-0034){ref-type="ref"}, [35](#embr201948885-bib-0035){ref-type="ref"}. Assessing all of the mapped O‐glycosylation sites to identify associations between O‐glycosites and protein annotations, we recently found that O‐glycans are over‐represented close to tandem repeat regions, protease cleavage sites, within propeptides, and on a select group of protein domains [28](#embr201948885-bib-0028){ref-type="ref"}, [30](#embr201948885-bib-0030){ref-type="ref"}, [36](#embr201948885-bib-0036){ref-type="ref"}. Although such general associations between the location of O‐glycans and protein functions may direct future investigations, the strategy does not define the function of site‐specific glycosylation. Further progress in discovering and defining novel functions of site‐specific glycosylation events requires direct quantitative analysis of potential biological responses induced by the loss of distinct GalNAc‐T isoforms, and such biological responses are not easily observed in single cell culture systems. We previously used an organotypic tissue model equipped with genetically engineered cells to decipher the function of elongated O‐glycans [29](#embr201948885-bib-0029){ref-type="ref"}. In the present study, we took advantage of this complex organotypic model of human epithelia and combined it with quantitative O‐glycoproteomics and phosphoproteomics to search for biological functions of site‐specific O‐glycosylation (Fig [1](#embr201948885-fig-0001){ref-type="fig"}B). With this combinatorial strategy, we demonstrate that loss of individual GalNAc‐T isoforms has distinct phenotypic consequences through their effect on selective biological pathways.

Results and Discussion {#embr201948885-sec-0002}
======================

Site‐specific glycosylation influences epithelial homeostasis and differentiation of human skin cells {#embr201948885-sec-0003}
-----------------------------------------------------------------------------------------------------

To probe the non‐redundant functions of individual GalNAc‐Ts, we developed an isogenic cell model in spontaneously immortalized human epidermal keratinocytes [37](#embr201948885-bib-0037){ref-type="ref"}. HaCaT cells undergo normal differentiation in organotypic cultures to form a stratified squamous epithelium and express O‐glycans in a differentiation‐dependent manner similar to human skin [29](#embr201948885-bib-0029){ref-type="ref"}, [37](#embr201948885-bib-0037){ref-type="ref"}. The model provides a strong tool to analyze the phenotypic consequences of losing individual GalNAc‐Ts and the effects on defined biological functions, including proliferation, differentiation, cell--cell interactions, cell--matrix interactions, and signaling. First, we characterized the GalNAc‐T repertoire in the HaCaT cell line by RNA sequencing and immunocytochemistry, demonstrating that the expression profiles of *GALNT* genes are comparable to human skin (Fig [1](#embr201948885-fig-0001){ref-type="fig"}C and D). Immunocytochemistry showed the localization of GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3; human skin and HaCaT 3D models expressed GalNAc‐Ts in a similar expression pattern, with GalNAc‐T2 primarily expressed in basal cells and broader expression of GalNAc‐T1 and GalNAc‐T3 in all epithelial layers (Fig [1](#embr201948885-fig-0001){ref-type="fig"}D). To investigate the importance of GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3 in the differentiation of human skin, we used ZFN nucleases and CRISPR/Cas9 to generate isogenic HaCaT cell lines with loss of GalNAc‐T1 (ΔT1), GalNAc‐T2 (ΔT2), or GalNAc‐T3 (ΔT3) (Fig [1](#embr201948885-fig-0001){ref-type="fig"}B). Successful targeting of individual single cell clones was identified by detecting indels in amplicon analysis and validated by Sanger sequencing ([Appendix Table S1](#embr201948885-sup-0001){ref-type="supplementary-material"}). In addition, the elimination of GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3 was confirmed by immunocytochemistry using mAbs for the individual enzymes (Fig [EV1](#embr201948885-fig-0001ev){ref-type="fig"}). RNAseq verified the reduction of the targeted GalNAc‐Ts in relevant knock‐out (KO) cells with a limited influence on other GalNAc‐Ts, except for a prominent increase in the expression of *GALNT5*, especially in *GALNT3* KO cells ([Dataset EV1](#embr201948885-sup-0003){ref-type="supplementary-material"}, [Appendix Fig S2](#embr201948885-sup-0001){ref-type="supplementary-material"}). In addition, we found no overall change in ST, T, STn, or Tn expression (Fig [EV1](#embr201948885-fig-0001ev){ref-type="fig"}).

![Characterization of *GALNT* KO cell lines\
*GALNT* KO cell lines in WT or *COSMC* KO (sc, "SimpleCell") background were stained for GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3, as well as T (with (ST (sialyl‐T) + T) or without (T) neuraminidase treatment), Tn, and STn (sialyl‐Tn) glycoforms using monoclonal antibodies and lectins. Scale bar---10 μm.](EMBR-21-e48885-g003){#embr201948885-fig-0001ev}

We used the set of engineered keratinocytes to form human tissue in a 3D organotypic skin model, enabling us to examine how distinct isoforms of GalNAc‐Ts affect epithelial formation. Organotypic cultures generated from wild‐type (WT) HaCaT keratinocytes had multiple layers of differentiating cells, with proliferation restricted to the single basal layer of K10‐negative cells, though with low levels of terminal keratinization as described previously (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E). Lack of GalNAc‐T1 caused a prominent phenotype with a distinct loss of normal architecture and changes in differentiation and stratification. ΔT1 tissue exhibited basal cells with flattened and spindle cell morphology (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E, red arrows). In addition, the stratum spinosum and granulosum were changed, with increased eosinophilic appearance, flattened cells, and to some extent pyknotic nuclei (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E, purple asterisks). Proliferating cells visualized by Ki67 staining were confined to the basal layer. Furthermore, several non‐differentiated cytokeratin 10 (K10)‐negative cell regions were found throughout the tissue, signifying delayed differentiation in some areas, whereas other areas appeared to exhibit increased differentiation (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E, red asterisks). In contrast, ΔT2 tissue presented with dramatically increased growth and height of the organotypic cultures (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E and F). An increased number of proliferating cells were observed, confined mostly to the basal layer (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E, green asterisks). No major change was seen in the differentiation pattern. Finally, the most significant changes were observed with elimination of GalNAc‐T3. ΔT3 tissues had a significantly increased number of non‐differentiating basal cells lacking K10 expression (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E, red asterisks; Fig [1](#embr201948885-fig-0001){ref-type="fig"}G). In addition, the overall tissue architecture was changed, though the proliferative Ki67‐positive cells were still confined to a single cell layer (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E). In addition, an abrupt change was observed between K10‐negative and K10‐positive cells, with the latter immediately exhibiting flattened nuclei (Fig [1](#embr201948885-fig-0001){ref-type="fig"}E, red arrows).

Next, we performed RNA sequencing to compare the expression profiles of conventionally grown WT HaCaT cells and HaCaT cells without GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3 ([Dataset EV1](#embr201948885-sup-0003){ref-type="supplementary-material"}). Analysis of the differential transcriptomes using the Benjamini--Hochberg procedure at an FDR‐adjusted *P* value of 0.05 identified rather limited sets of targets that consistently changed in all three clones of each *GALNT* isoform KO compared to WT ([Dataset EV1](#embr201948885-sup-0003){ref-type="supplementary-material"}). In addition, we looked at a distinct gene set involved in keratinocyte differentiation, despite lacking significance in some of the isoform KOs (Fig [1](#embr201948885-fig-0001){ref-type="fig"}H). The expression of markers defining different stages of skin differentiation confirmed that ΔT1 caused a slightly mixed phenotype with a mild increase in the expression of most differentiation markers (Fig [1](#embr201948885-fig-0001){ref-type="fig"}H). In contrast, minor changes were observed in ΔT2 cells, with a slight decrease in differentiation markers consistent with a limited change in the differentiation pattern of basal cells. ΔT3 induced the largest transcriptomic changes, with significant downregulation of keratins (KRT1, KRT10, KRT13), transglutaminase 1 (TGM1), filaggrin (FLG), and involucrin (IVL), which are all associated with decreased differentiation consistent with the observed phenotype. In addition, we observed an effect on the expression of NOTCH receptors and the Notch signaling responsive gene HES5 (Fig [1](#embr201948885-fig-0001){ref-type="fig"}H).

Differential phosphoproteomic analysis reveals that individual GalNAc‐Ts control distinct biological pathways {#embr201948885-sec-0004}
-------------------------------------------------------------------------------------------------------------

To appreciate the changes in signaling networks associated with knocking out individual *GALNT* isoforms, we performed differential proteomic and phosphoproteomic analyses of TMT 10‐plex‐labeled, TiO~2~‐enriched ΔT1, ΔT2, and ΔT3 tryptic digests (2 clones of each) compared to WT by tandem mass spectrometry (MS/MS) (Fig [2](#embr201948885-fig-0002){ref-type="fig"}A). MS/MS analysis of sample pre‐enrichment was used to evaluate proteomic changes. Log10 transformed TMT ratios \> 2 SD from the median, consistent in both clones, and within 95% of the WT2/WT1 confidence interval were considered significant. A total of 7930 unique phosphosites on 2,938 proteins were identified (Fig [2](#embr201948885-fig-0002){ref-type="fig"}B; [Dataset EV2](#embr201948885-sup-0004){ref-type="supplementary-material"}). Using the defined selection criteria, we identified 41, 55, and 180 differentially regulated phosphosites in ΔT1, ΔT2, and ΔT3 cells, respectively (Fig [2](#embr201948885-fig-0002){ref-type="fig"}B and C). The different *GALNT* isoform KOs each generated unique phosphorylation signatures associated with distinct cellular pathways, as shown by GO term enrichment analysis of significantly changed phosphoprotein identities (Fig [2](#embr201948885-fig-0002){ref-type="fig"}D). First, ΔT1 exhibited phosphoproteomic changes associated with cytoskeleton organization. For example, reduced phosphorylation of the important regulator of microtubule dynamics, stathmin at Ser63, suggests alterations in cell cycle progression through destabilization of microtubule assembly [38](#embr201948885-bib-0038){ref-type="ref"}, [39](#embr201948885-bib-0039){ref-type="ref"}. Other phosphorylation changes suggested an effect on cell cycle and proliferation, as well as terminal differentiation. Second, ΔT2 exhibited phosphoproteomic changes associated with cell adhesion and migration. For example, decreased phosphorylation at Ser418 of cortactin, a major protein involved in podosome formation, suggests impaired interaction with regulatory proteins required for cell motility [40](#embr201948885-bib-0040){ref-type="ref"}. Altered podosome formation may also affect extracellular matrix (ECM) remodeling and cell--matrix adhesion. In addition, ΔT2 was associated with changes in phosphorylation related to protein synthesis, such as several eukaryotic translation initiation factors, and other mRNA‐binding proteins were identified as differential phosphotargets. Third, ΔT3 had the strongest effect on signaling networks and induced changes in phosphorylation associated with cell cycle progression, DNA repair, and protein degradation (Fig [2](#embr201948885-fig-0002){ref-type="fig"}D; [Dataset EV2](#embr201948885-sup-0004){ref-type="supplementary-material"}). Importantly, the differentially phosphorylated targets in the *GALNT* KO cell lines were independent from changes in the proteome (Fig [EV2](#embr201948885-fig-0002ev){ref-type="fig"}), indicating that individual GalNAc‐Ts control distinct biological pathways.

![Phosphoproteomic analysis\
Strategy for differential phosphoproteomics of HaCaT *GALNT* KO cell lines, where the Gaussian distributions and the Venn diagram represent selection criteria.Analysis of differentially phosphorylated peptides. Upregulated or downregulated phosphopeptides in *GALNT* KOs were considered significant, if phosphopeptides were identified in both clones more than 2× SD away from the median, and given the same phosphopeptides were within the normal variation of two wild‐type biological replicates. The Venn diagram illustrates the selection criteria, where the color scheme corresponds to the Gaussian distribution illustration above. The bar graph depicts numbers of unique differential phosphosites in the individual *GALNT* KOs.The Venn diagram represents overlap between differential phosphosites identified in the different *GALNT* isoform KOs.GO terms (DAVID) associated with phosphoproteins identified in the 3 differential datasets. *P* value (Benjamini multiple comparison adjusted) of 0.05 is marked with a dashed line.](EMBR-21-e48885-g004){#embr201948885-fig-0002}

![Overlap between differential proteome and phosphoproteome\
Venn diagrams indicate overlap between proteins identified in differential proteomic and phosphoproteomic analyses of the individual *GALNT* isoform KOs.](EMBR-21-e48885-g005){#embr201948885-fig-0002ev}

Differential glycoproteomic analysis reveals that individual GalNAc‐Ts control distinct subsets of protein targets {#embr201948885-sec-0005}
------------------------------------------------------------------------------------------------------------------

To investigate the molecular link between individual GalNAc‐Ts and the distinct biological pathways affected by the loss of each transferase, we investigated which proteins were glycosylated by GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3, and where on the select protein targets the GalNAc/GalGalNAc residues were localized. We previously developed techniques that allow the identification of site‐specific O‐glycosylation on a proteome‐wide basis, which has enabled high‐throughput mapping of sites of O‐glycan attachment in proteomes from both cell lines and tissues [28](#embr201948885-bib-0028){ref-type="ref"}, [30](#embr201948885-bib-0030){ref-type="ref"}. Furthermore, we have shown that targeted KO of individual *GALNT*s allows for discovery of GalNAc‐T isoform‐specific substrates [32](#embr201948885-bib-0032){ref-type="ref"}, [33](#embr201948885-bib-0033){ref-type="ref"}, [34](#embr201948885-bib-0034){ref-type="ref"}, [41](#embr201948885-bib-0041){ref-type="ref"}. Two approaches were used to characterize the differential O‐glycoproteomes of ΔT1, ΔT2, and ΔT3. Initially, for ease of analysis, stable isotope dimethyl‐labeled tryptic digests of isogenic cell pairs on a HaCaT *COSMC* KO background were coupled to VVA enrichment of desialylated glycopeptides (Fig [3](#embr201948885-fig-0003){ref-type="fig"}A). Dimethyl labeling is a rather inexpensive method for quantitative proteomics but has a few limitations, such as non‐identical retention times due to deuterium shift and only three different quantification channels [42](#embr201948885-bib-0042){ref-type="ref"}. We subsequently analyzed the effect of *GALNT* KOs on the more biologically relevant WT background. We have previously demonstrated efficient enrichment of desialylated ST structures by PNA/Jacalin lectin chromatography in epithelial cell lines and clinical specimens [28](#embr201948885-bib-0028){ref-type="ref"}, [43](#embr201948885-bib-0043){ref-type="ref"}, and to allow side by side comparison of differentially modified targets in different cell lines, we used TMT labeling for this set of experiments [44](#embr201948885-bib-0044){ref-type="ref"}. TMT 10plex‐labeled tryptic digests of three individual clones of each ΔT1, ΔT2, and ΔT3 were compared to WT in a single Jacalin LWAC run (Fig [3](#embr201948885-fig-0003){ref-type="fig"}A). Only the TMT ratios consistently changed in all three clones were considered significant (Table [1](#embr201948885-tbl-0001){ref-type="table"}; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). Each of the methods identified distinct subsets of GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3‐specific targets (Fig [3](#embr201948885-fig-0003){ref-type="fig"}B; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). An assessment of the isoform‐specific glycosites identified in the WT cell background by the TMT method revealed 45 GalNAc‐T1 sites, 40 GalNAc‐T2 sites, and 34 GalNAc‐T3 sites in glycopeptides carrying single HexHexNAc residues (Fig [3](#embr201948885-fig-0003){ref-type="fig"}C). Considering glycosites on glycopeptides containing multiple HexHexNAc residues, the numbers of identified sites increased to 69 GalNAc‐T1 sites, 51 GalNAc‐T2 sites, and 56 GalNAc‐T3 sites (Fig [3](#embr201948885-fig-0003){ref-type="fig"}C). An independent analysis using Qlucore Omics Explorer software highlighted some of the same isoform‐specific targets that contributed to the overall variation in the data (Fig [3](#embr201948885-fig-0003){ref-type="fig"}E). The majority of isoform‐specific glycosylation sites were not affected by knocking out alternative isoforms, but 3% of the glycosites were affected by the loss of each of the three enzymes. Similarly, approximately 15% of glycosites were affected by at least two isoforms (Fig [3](#embr201948885-fig-0003){ref-type="fig"}D). Interestingly, 26% of GalNAc‐T2 single sites were found in other published and unpublished datasets in HepG2 cells and HEK293 cells, where GalNAc‐T2 represents one of the predominant isoforms [32](#embr201948885-bib-0032){ref-type="ref"}, [34](#embr201948885-bib-0034){ref-type="ref"}. Lower consistency was observed for GalNAc‐T1 or GalNAc‐T3 single‐site targets, which can partially be explained by a larger proportion of glycosites residing on peptides with multiple glycosites. Regardless, some of the GalNAc‐T1 and GalNAc‐T3 targets fit well with those identified previously in HepG2 and LS174 cells, respectively [32](#embr201948885-bib-0032){ref-type="ref"}, [33](#embr201948885-bib-0033){ref-type="ref"}. A total of 47, 82, and 82 glycosites glycosylated by GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3, respectively, on peptides with single or multiple HexNAcs were identified using the dimethyl labeling approach, with little overlap with the TMT dataset (Fig [3](#embr201948885-fig-0003){ref-type="fig"}C). Some correlations were found with previously published differential glycoproteomic datasets on the *COSMC* KO background [32](#embr201948885-bib-0032){ref-type="ref"}, [33](#embr201948885-bib-0033){ref-type="ref"}.

![O‐glycoproteomic analysis\
ANumbers of quantified O‐glycopeptides identified with ETD fragmentation with either dimethyl labeling or TMT labeling approach in *COSMC* KO or WT background, respectively.BNumbers of differentially glycosylated peptides in the two approaches, using select filters on quantification values.CNumbers of unambiguous unique differential O‐glycosites identified with the two different approaches. The stacked bar graph differentiates between glycosites identified on peptides with single and multiple HexNAc/HexHexNAc modifications.DThe Venn diagram represents overlap between differential single HexNAc/HexHexNAc glycosites in the three differential datasets (pooled targets from both approaches).EAnalysis of differential glycosites identified with the TMT labeling approach using the Qluqore Omics Explorer software. The heatmap represents O‐glycosites most significantly contributing to sample variation, using ANOVA with a *q* value cutoff of 0.1, where each compared sample consists of three individual KO clones. Each horizontal line depicts the median quantification of glycopeptides contributing to the same glycosite. Alternative differentially glycosylated site positions are separated by semicolons on sites derived from glycopeptides with multiple HexNAc/HexHexNAc modifications.F, GGO term analysis of differentially glycosylated protein identifications from both approaches (DAVID, *q* ≤ 0.05, Benjamini adjusted). (F) GO terms found in all differential datasets associated with subcellular location and common glycoprotein properties. (G) Differential GO terms, found in only one of the three differential datasets. *P* value (Benjamini multiple comparison adjusted) of 0.05 is marked with a dashed line.HTop downregulated unambiguous single HexNAc/HexHexNAc targets found in all three clones of individual *GALNT* KO (not changed in other isoforms) with the TMT labeling approach.](EMBR-21-e48885-g006){#embr201948885-fig-0003}

###### 

Isoform‐selective glycosites

  WT TMT Jacalin (∆T1/wt ≤ 0.5; ∆T2/wt \> 0.5; ∆T3/wt \> 0.5 (in all 3 clones))                                                                                                                                     
  ------------------------------------------------------------------------------- ---------- ----------------------------------------------------- ------------------------ --------------------- ------- --------- -------
  FLRT3                                                                           402; 403   Leucine‐rich repeat transmembrane protein FLRT3       ER, CM, Secr             Development           1.097   5         10.79
  LDLR                                                                            726        Low‐density lipoprotein receptor                      CM, Endosome, Lysosome   LDL uptake            0.840   5         6.05
  ERLIN2                                                                          336        ER lipid raft associated 2                            ER                       ERAD                  1.108   11        38.35
  CD9                                                                             177        CD9 antigen                                           CM                       Platelet activation   1.047   5         16.23
  EXTL3                                                                           563        Exostosin‐like 3                                      ER, Golgi                HS biosynthesis       0.976   4         5.22
  SEL1L                                                                           88         Protein sel‐1 homolog 1                               ER                       ERAD/ERQC             0.910   14        23.68
  GALNT5                                                                          179        Polypeptide GalNAc transferase 5                      Golgi                    O‐glycosylation       0.775   8         9.57
  MIA3                                                                            1,099      Transport and Golgi organization protein 1 homolog    ER                       Cargo loading         0.762   30        21.19
  ST6GAL1                                                                         65; 66     ST6 beta‐galactosamide alpha‐2,6‐sialyltranferase 1   Golgi                    Glycosylation                 1 or ND   
  MAN1B1                                                                          154        ER alpha‐1,2‐mannosidase                              ER                       ERQC                  0.949   9         19.89
  TGOLN2                                                                          202        Trans‐Golgi network integral membrane protein 2       TGN, CM                  Vesicular transport   0.884   12        26.67
  IGFBP7                                                                          230; 239   Insulin‐like growth factor binding protein 7          Secr                     IGF binding                   1 or ND   
  IGF1R                                                                           684        Insulin‐like growth factor 1 receptor                 CM                       Survival (RTK)        1.146   16        14.12
  NUCB1                                                                           443        Nucleobindin 1                                        Golgi, Secr              IGF transport         0.953   19        44.9
  STIM1                                                                           34         Stromal interaction molecule 1                        ER, CM                   Ca(2+) sensing        0.784   18        32.85
  MIA3                                                                            293        Transport and Golgi organization protein 1 homolog    ER                       Cargo loading         0.762   30        21.19
  PNPLA6                                                                          3; 10      Patatin‐like phospholipase domain containing 6        ER                       PtdCho metabolism     1.014   11        9.59
  TGFBR2                                                                          39         Transforming growth factor, beta receptor type II     CM                       Cell signaling                1 or ND   
  CA9                                                                             115        Carbonic anhydrase 9                                  CM                       pH regulation                 1 or ND   
  RTN4RL1                                                                         321        Reticulon 4 receptor‐like 1                           CM                       Receptor              0.997   9         24.75
  CKAP4                                                                           471        Cytoskeleton‐associated protein 4                     ER, CM                   ER anchoring          0.769   34        21.9

  WT TMT Jacalin (∆T2/wt ≤ 0.5; ∆T1/wt \> 0.5; ∆T3/wt \> 0.5 (in all 3 clones))                                                                                                                                                 
  ------------------------------------------------------------------------------- ---------- --------------------------------------------------------- -------------------- --------------------------------- ------- --------- -------
  F11R                                                                            133        Junctional adhesion molecule A                            CM, tight junction   Cell adhesion                     0.846   12        47.49
  TACSTD2                                                                         93         Tumor‐associated calcium signal transducer 2              CM                   Putative growth factor receptor   1.075   14        38.39
  PRCP                                                                            39         Lysosomal Pro‐X carboxypeptidase                          Lysosome             Protease                          1.146   7         16.94
  CTSD                                                                            63         Cathepsin D                                               Secr, Lysosome       Protease                          0.956   26        62.62
  MMP14                                                                           313        Matrix metallopeptidase 14                                CM                   Protease                          1.044   18        32.82
  OS9                                                                             529        Osteosarcoma amplified 9, ER lectin                       ER                   ERAD/ERQC                         0.996   6         11.39
  GPC1                                                                            510; 522   Glypican 1                                                CM, ECM, Endosome    HSPG                              0.975   16        38.17
  TMTC3                                                                           831        Transmembrane and tetratricopeptide repeat containing 3   ER                   Glycosylation                     1.035   15        19.56
  NUCB2                                                                           408        Nucleobindin 2                                            Secr, Golgi          Ca(2+) binding                    0.774   11        30.24
  COL17A1                                                                         1284       Collagen, type XVII, alpha 1                              Basement M           Cell--matrix adhesion             0.930   28        21.24
  HS2ST1                                                                          297        Heparan sulfate 2‐O‐sulfotransferase 1                    Golgi                HS biosynthesis                   0.951   4         14.89
  NECTIN2                                                                         95         Herpes virus entry mediator B                             CM                   Cell adhesion                             1 or ND   
  TGOLN2                                                                          318        Trans‐Golgi network integral membrane protein 2           TGN, CM              Vesicular transport               1.044   12        26.67

  WT TMT Jacalin (∆T3/wt ≤ 0.5; ∆T1/wt \> 0.5; ∆T2/wt \> 0.5 (in all 3 clones))                                                                                                                                                        
  ------------------------------------------------------------------------------- ------------------------ --------------------------------------------------- --------------------- ------------------------------------ ------- ---- -------
  JAG1                                                                            87                       Jagged 1                                            CM                    Differentiation (Notch ligand)       1.287   11   10.51
  DSG3                                                                            601; 602; 606            Desmoglein 3                                        CM, desmosome         Cell adhesion                        1.621   29   36.04
  CELSR1                                                                          2306; 2307; 2310; 2311   Cadherin, EGF LAG seven‐pass G‐type receptor 1      CM                    Cell signaling                       1.163   7    3.65
  AGRN                                                                            1294; 1295               Agrin                                               CM, ECM               HSPG                                 1.051   24   16.14
  FGFBP1                                                                          62                       Fibroblast growth factor binding protein 1          CM, ECM               Mitogenic carrier protein            1.506   4    24.79
  LSR                                                                             118                      Lipolysis stimulated lipoprotein receptor           CM                    Lipoprotein binding                  0.855   12   22.8
  GALNT5                                                                          260                      Polypeptide GalNAc‐transferase 5                    Golgi                 O‐glycosylation                      1.017   8    9.57
  TGOLN2                                                                          174;175                  Trans‐Golgi network integral membrane protein 2     TGN, CM               Vesicular transport                  1.110   12   26.67
  FLRT3                                                                           397; 402; 405; 407       Leucine‐rich repeat transmembrane protein FLRT3     ER, CM, Secr          Development                          1.294   5    10.79
  LRPAP1                                                                          134                      Alpha‐2‐macroglobulin receptor‐associated protein   ER, Golgi, Endosome   Chaperone for LDLR related protein   1.083   18   40.34
  GLG1                                                                            1083                     Golgi apparatus protein 1                           Golgi                 FGF binding                          0.951   33   31.81
  B2M                                                                             106                      Beta‐2‐microglobulin                                Secr                  Antigen presentation                 0.841   10   48.74
  CD59                                                                            76                       CD59 molecule, complement regulatory protein        CM, Secr              Complement binding                   0.869   6    35.94
  HYOU1                                                                           589; 590                 Hypoxia upregulated protein 1                       ER                    Cytoprotection                       0.962   37   43.54
  TACSTD2                                                                         88                       Tumor‐associated calcium signal transducer 2        CM                    Putative growth factor receptor      0.974   14   38.39
  FAT2                                                                            4036                     Protocadherin Fat 2                                 CM, cell junction     Cell migration                       1.034   63   19.54

CM, cell membrane; ER, endoplasmic reticulum; ERAD, ER‐associated protein degradation; ERQC, ER quality control; HSPG, heparan sulfate proteoglycan; ND, not detected; Secr, secreted; TGN, trans‐Golgi network.

Semicolons separate alternative differentially glycosylated site positions (derived from glycopeptides with multiple HexNAc/HexHexNAc modifications).

Average of three clone ratios (KO/wt); filtered for values \> 0.75.

In conclusion, we unambiguously identified 67, 88, and 63 single‐GalNAc/GalGalNAc glycosites for GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3, respectively. We found limited overlap between the identified glycosites between each GalNAc‐T isoform, supporting the validity of the strategy and identified candidates. Comparison of glycoprotein and glycosite identities for each isoform between the two methods has shown variable overlap ([Appendix Fig S1](#embr201948885-sup-0001){ref-type="supplementary-material"}, [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). Almost a third of glycoprotein substrates for GalNAc‐T2 and GalNAc‐T3 identified with TMT labeling were also identified with dimethyl labeling, whereas very little overlap was observed for GalNAc‐T1 ([Appendix Fig S1](#embr201948885-sup-0001){ref-type="supplementary-material"}). However, the majority of commonly identified protein substrates were glycosylated at different positions using the two methods. This is not surprising given the different genetic backgrounds of the cells used for the analysis, as well as the distinct methodological approaches affecting the chemical properties and the dynamic range of detected glycopeptides. Transcriptomic and proteomic differences from WT cells should also be taken into account. Finally, it should be mentioned that similar to dimethyl labeling, the TMT labeling has its limitations, such as protease coverage, likely leading to underrepresentation of juxtamembrane sites and potential bias by select lectin enrichment of heavily glycosylated peptides.

Next, we performed GO term enrichment analysis on distinct subsets of targets identified for GalNAc‐T1, GalNAc‐T2, and GalNAc‐T3. As expected, all three isoform‐specific targets shared GO terms associated with the general properties of glycoproteins, such as signal peptide and transmembrane structural elements, as well as cell membrane localization or secretion from the cell (Fig [3](#embr201948885-fig-0003){ref-type="fig"}F). In addition, each set of isoform‐specific targets exhibited associations with distinct cellular processes (Fig [3](#embr201948885-fig-0003){ref-type="fig"}G), with GalNAc‐T1 targets associated with components of the endomembrane system, GalNAc‐T2 targets associated with cell--ECM adhesion, and GalNAc‐T3 targets associated with epithelial differentiation and cell migration. A few observations emerge based on the location of the top five downregulated single HexHexNAc glycosites found in individual *GALNT* isoform KOs. GalNAc‐T1 and GalNAc‐T2 glycosites were positioned mostly in unstructured regions, where GalNAc‐T2‐specific sites were commonly found close to protease cleavage sites. In contrast, the main GalNAc‐T3 target glycosites resided on structural domains (Fig [3](#embr201948885-fig-0003){ref-type="fig"}H). It is important to consider other factors that could play a role in defining enzyme preferences, including subcompartmentalization of the secretory pathway and complex formation between glycosyltransferases [45](#embr201948885-bib-0045){ref-type="ref"}, [46](#embr201948885-bib-0046){ref-type="ref"}. Furthermore, deletion or overexpression of individual isoforms will affect the overall O‐glycosylation network of initiating and follow‐up enzymes, likely causing changes in the O‐glycoproteomic landscape [47](#embr201948885-bib-0047){ref-type="ref"}.

GalNAc‐T1 is associated with integrity of the endomembrane system in human keratinocytes {#embr201948885-sec-0006}
----------------------------------------------------------------------------------------

The GalNAc‐T1‐specific targets included several ion antiporters crucial for maintaining intracellular pH and Ca^2+^ homeostasis (SLC9A1, TMEM165; Fig [3](#embr201948885-fig-0003){ref-type="fig"}H; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}) [48](#embr201948885-bib-0048){ref-type="ref"}, [49](#embr201948885-bib-0049){ref-type="ref"}, [50](#embr201948885-bib-0050){ref-type="ref"}. Importantly, SLC9A1, the plasma membrane Na^+^/H^+^ exchanger NHE1, was identified as a differentially phosphorylated target, with the exact phosphosite known to regulate the activity of the protein ([Dataset EV2](#embr201948885-sup-0004){ref-type="supplementary-material"}) [51](#embr201948885-bib-0051){ref-type="ref"}. Intracellular pH measurements under steady‐state conditions indicated that ΔT1 cells maintained a lower intracellular pH than WT (Fig [4](#embr201948885-fig-0004){ref-type="fig"}D). Another target, TMEM165, functions as a calcium/proton transporter and is involved in calcium and lysosomal pH homeostasis [49](#embr201948885-bib-0049){ref-type="ref"}. A large number of targets associated with endomembrane compartments urged us to look at the prevalence of various intracellular organelles in ΔT1. Differences were observed in the intracellular trafficking compartments, with altered clathrin (Fig [4](#embr201948885-fig-0004){ref-type="fig"}A) and Rab5 (Fig [4](#embr201948885-fig-0004){ref-type="fig"}B) distribution and reduced numbers of recycling endosomes visualized by the loss of Rab11 staining (Fig [4](#embr201948885-fig-0004){ref-type="fig"}C). In addition, we observed GalNAc‐T1‐selective glycosylation of several targets involved in skin differentiation and homeostasis, including a few recycling receptors. This includes the low‐density lipoprotein (LDL) receptor, transforming growth factor β receptor 2 (TGFBR2), and insulin‐like growth factor 1 receptor (IGF1R), and O‐glycans have been suggested to play a functional role in both IGF1R signaling and LDL receptor function [52](#embr201948885-bib-0052){ref-type="ref"}, [53](#embr201948885-bib-0053){ref-type="ref"}. Mutation of the glycosylated amino acid on LDLR (Thr726Ile) has been identified in familial hypercholesterolemia and shown to reduce receptor activity to less than 5% in *ex vivo* assays [54](#embr201948885-bib-0054){ref-type="ref"}. Therefore, we tested receptor activity in ΔT1 by monitoring the uptake of pHrodo‐labeled LDL, which fluoresces when taken up into endosomes/lysosomes. The uptake pattern in ΔT1 differed from the pattern in WT, with more dispersed localization of pHrodo‐labeled LDL in the ΔT1 cells and lower grade of co‐localization in lysosomes (Fig [EV3](#embr201948885-fig-0003ev){ref-type="fig"}). In general, ΔT1 cells poorly engaged in lysosome formation even 2.5 h after adding the labeled LDL. However, we cannot exclude that the pattern we observed is a result of alterations of the trafficking system. Furthermore, we found downregulation of genes involved in cholesterol synthesis in ΔT1 ([Dataset EV1](#embr201948885-sup-0003){ref-type="supplementary-material"}). Given that LDL receptor is part of a feedback system that regulates cholesterol homeostasis, these results could suggest future exploration of site‐specific glycosylation as a regulator of LDLR function.

![Pathways affected by isoform‐specific O‐glycosylation\
A--DGalNAc‐T1 affects the organization and function of the endomembrane system. HaCaT WT and *GALNT1* KO cells were stained for intracellular trafficking markers (scale bar---10 μm). (A) Clathrin; (B) Rab5; and (C) Rab11. (D) Steady‐state intracellular pH measurement in in HaCaT WT and *GALNT1* KO cells. Data are presented as average ± SD of 2 independent experiments. ANOVA followed by Dunnet\'s multiple comparison test was used to compare mean intracellular pH of three different clones of *GALNT1* KOs to WT. \**P* ≤ 0.05.EGalNAc‐T2 is important for cell to matrix adhesion. HaCaT WT and *GALNT2* KO cells were used in a cell to matrix adhesion assay using plates coated with different ECM components. Data are presented as average + SD of three independent experiments and are normalized to WT. ANOVA followed by Dunnet\'s multiple comparison test was used to compare mean relative adhesion of two different clones of *GALNT2* KOs to WT. \**P* ≤ 0.05; \*\**P* ≤ 0.01.FWestern blot for GalNAc‐T2‐specific target and hemidesmosome component COL17A1.GQuantification of Western blot bands for COL17A1 (full length) normalized to β actin.HDepiction of COL17A1 protein, including position of GalNAc‐T2‐specific O‐glycosite and proteolytic processing sites.IGalNAc‐T2 may affect tight junction formation and integrity. Upper panel, TEM of WT and *GALNT2* KO organotypic tissue sections, where tight junctions are marked with asterisks. Lower panel, IF staining of WT and *GALNT2* KO for tight junction marker occludin (scale bar---50 μm). Inserts depict 3× zoomed in partial images (scale bar---50 μm).JExpression of cyclin A (green) in HaCaT WT and *GALNT3* KO organotypic tissue, visualized by IF (scale bar---20 μm).KThe cartoon summarizes the effects of individual *GALNT* isoform KOs on signaling networks and subcellular location of protein substrates based on differential phosphoproteomic and O‐glycoproteomic analyses.L--NCo‐culture of HaCaT WT or *GALNT3* KO keratinocytes with N/TERT1 keratinocytes induces cellular differentiation. Cells co‐cultured on coverslips were stained for cleaved Notch 1 intracellular domain (L), cytokeratin 10 (M), or GalNAc‐T3 (N; inserts depict 2× zoomed in partial images (scale bar---20 μm)). Green---relevant staining, red---N/TERT1 cells (labeled with CMTMTR), and blue---DAPI, scale bar---20 μm. Boundaries between HaCaT and N/TERT‐1 cells in the green panel of (L) are marked with a dashed line.](EMBR-21-e48885-g008){#embr201948885-fig-0004}

![LDL trafficking in HaCaT WT and *GALNT1* KO cells\
Cells grown on coverslips were cultured in media with lipoprotein‐depleted serum for 24 h, followed by pulsing with Lysotracker Red DND‐99 (−1 h) and LDL‐pHrodo (0 h). Coverslips were fixed at 1 h (upper panels), 1.5 h (middle panels), and 2.5 h (lower panels) and imaged using confocal microscopy. Scale bar---10 μm.](EMBR-21-e48885-g007){#embr201948885-fig-0003ev}

Integration of the glycoproteomics, proteomics, and phosphoproteomics data supported the proposed role of GalNAc‐T1 on the endomembrane system. It is however, important to note, that an alternative explanation for the quantitative enrichment of endomembrane compartment proteins in ΔT1 cells could be that it is a secondary effect of differentiation. Increased cell size and structural reorganization of the secretory pathway and vesicular transport during differentiation has previously been suggested for keratinocytes [55](#embr201948885-bib-0055){ref-type="ref"} and would fit well with the upregulation of differentiation markers and decreased cytosolic pH.

GalNAc‐T2 regulates cell--ECM adhesion in human keratinocytes {#embr201948885-sec-0007}
-------------------------------------------------------------

Among the identified GalNAc‐T2‐specific targets, we found several adhesion molecules (NRP2, F11R, PODXL, NECTIN2, CD99, PTPRS, BCAM, ITGAX, ROBO1, SEMA4D) and components of the basal lamina and ECM, including MATN2, COL4A1, ADAMTSL4, NID1, MMP14, ECM1, MMP1, LGALS3BP, COL12A1, CTSD, LAD1, VWA1, ECM1, and COL17A1 (Fig [3](#embr201948885-fig-0003){ref-type="fig"}G; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). Immunofluorescence staining of components of different cell adhesion elements, including those of hemidesmosomes, desmosomes, adherens junctions, and tight junctions, revealed altered expression patterns for integrin alpha 6, as well as tight junction markers claudin 1 and occludin (Fig [4](#embr201948885-fig-0004){ref-type="fig"}I, lower panel; Fig [EV4](#embr201948885-fig-0004ev){ref-type="fig"}). Furthermore, transmission electron microscopy (TEM) of organotypic tissue sections revealed reduced tight junction content in the ΔT2 organotypic skin (Fig [4](#embr201948885-fig-0004){ref-type="fig"}I, upper panel). JAM1 (F11R), a component of tight junctions, was identified as a selective GalNAc‐T2 target (Fig [3](#embr201948885-fig-0003){ref-type="fig"}H; Table [1](#embr201948885-tbl-0001){ref-type="table"}; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}), but whether it has a direct impact on tight junction formation is unclear (Fig [EV4](#embr201948885-fig-0004ev){ref-type="fig"}). No change in surface expression was observed for integrin beta 4, integrin alpha 3, desmoglein 1, desmocollin 2, CD44, or collagen 17 α1 (Fig [EV4](#embr201948885-fig-0004ev){ref-type="fig"}). Together with the O‐glycoproteomic data, these findings suggest that GalNAc‐T2 function is critical for selective adhesion components including those important for cell--ECM interactions. To test this hypothesis, we evaluated the adhesion of ΔT2 cells to different ECM components and found that ΔT2 cells exhibited a weaker association with fibronectin, laminin, collagen 1, and fibrinogen than WT cells (Fig [4](#embr201948885-fig-0004){ref-type="fig"}E).

![Cell adhesion in HaCaT WT and *GALNT2* KO cells\
Cells grown on coverslips were fixed, permeabilized, and stained for cell--cell and cell--matrix adhesion molecules, followed by imaging by confocal microscopy. Green---relevant staining and blue---DAPI. Scale bar---50 μm.](EMBR-21-e48885-g009){#embr201948885-fig-0004ev}

As seen in other cell systems [41](#embr201948885-bib-0041){ref-type="ref"}, many of the GalNAc‐T2 glycosites were found to reside in protein regions associated with proteolytic processing (CTSD, PRCP, COL17A1, BCAM, LRP1) (Fig [3](#embr201948885-fig-0003){ref-type="fig"}H; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). One such glycosite is residing at the fourth non‐collagenous domain of COL17A1 cleaved by plasmin and harboring a few known mutations in skin blistering diseases [56](#embr201948885-bib-0056){ref-type="ref"}, [57](#embr201948885-bib-0057){ref-type="ref"}. Lack of protection due to the loss of a glycosylation site could enhance plasmin cleavage and partially explain the impaired cell to matrix adhesion in ΔT2 cells. In support of this, we observed decreased amounts of full‐length and shed COL17A1 on Western blot (Fig [4](#embr201948885-fig-0004){ref-type="fig"}F--H), but total protein levels were unchanged according to MS (Table [1](#embr201948885-tbl-0001){ref-type="table"}, [Dataset EV3](#embr201948885-sup-0005){ref-type="supplementary-material"} and [EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}), suggesting that additional cleavage of the ectodomain may be enhanced in ΔT2.

Cleavage of the full‐length and shed domain by plasmin results in disruption of the C‐terminal region important for interaction with laminin 5 and creates neoepitopes for linear IgA dermatosis antibodies [58](#embr201948885-bib-0058){ref-type="ref"}, [59](#embr201948885-bib-0059){ref-type="ref"}. In this context, we found LAD1, another classical IgA dermatosis marker, as a GalNAc‐T2 target. The basal cell adhesion molecule (BCAM) was also among the selective targets with the glycosylation site in close proximity to protease cleavage sites. It is tempting to speculate that GalNAc‐T2 could affect BCAM shedding known to modulate interaction of BCAM with laminin 5 [60](#embr201948885-bib-0060){ref-type="ref"}, [61](#embr201948885-bib-0061){ref-type="ref"}. Moreover, an SNP in the glycosylated Ser539 of BCAM differentiates two different Lutheran blood group antigens [62](#embr201948885-bib-0062){ref-type="ref"}. In conclusion, these results suggest that GalNAc‐T2 impacts the stability of cell--matrix adhesion, correlating well with the basal expression pattern of GalNAc‐T2 in both the epidermis and several other epithelia.

GalNAc‐T3 regulates epithelial differentiation in human keratinocytes {#embr201948885-sec-0008}
---------------------------------------------------------------------

Among the GalNAc‐T3‐specific targets, we found an enrichment of proteins containing EGF‐like Ca^2+^ binding domains, as well as some growth factor binding and heparin binding proteins (Fig [3](#embr201948885-fig-0003){ref-type="fig"}G; [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). Interestingly, we found specific sites in the Notch ligand Jagged‐1, the adhesive proteins, protocadherin Fat 2, and desmoglein 3, which are involved in cellular differentiation and proliferation (Table [1](#embr201948885-tbl-0001){ref-type="table"}, [Dataset EV4](#embr201948885-sup-0006){ref-type="supplementary-material"}). Consistent with delayed differentiation in the ΔT3 skin, we detected increased expression of cyclin A in the K10‐negative skin layers (Fig [4](#embr201948885-fig-0004){ref-type="fig"}J). The GalNAc‐T3‐specific glycosylation on position T87 in Jagged‐1 could potentially explain the prominent altered differentiation phenotype observed in ΔT3 skin. Interestingly, Jagged‐1 harboring a mutation at Thr87 has been reported to have increased affinity for the Notch1 receptor through fixation of the catch‐bond interaction [63](#embr201948885-bib-0063){ref-type="ref"}. In order to address the potency of Jagged‐1^T3KO^ to induce Notch1 signaling, we co‐cultured HaCaT WT or ΔT3 keratinocytes with N/TERT1 immortalized keratinocytes and assessed Notch1 activation by nuclear expression of cleaved Notch1 intracellular domain (NICD). In addition, we evaluated differentiation by K10 staining. Co‐culture of N/TERT1 WT and HaCaT ΔT3 cells induced robust differentiation of N/TERT1 cells, which were mostly organized into compact piles, strongly positive for nuclear cleaved NICD, and increased K10 expression (Fig [4](#embr201948885-fig-0004){ref-type="fig"}L--N). In contrast, co‐culture of WT HaCaT and N/TERT1 keratinocytes only induced limited K10 expression and failed to induce organized piles of keratinocytes positive for NICD (Fig [4](#embr201948885-fig-0004){ref-type="fig"}L--N). Furthermore, a lower level of Notch1 intracellular domain cleavage was observed in HaCaT WT, with fewer cells positive for cleaved NICD in HaCaT ΔT3 cells. The combined results support the potential role of GalNAc‐T3‐specific O‐glycosylation on differentiation possibly through fine‐tuning Jagged--Notch interactions. We also investigated Notch1 signaling in the organotypic models by visualizing localization of cleaved NICD, which was primarily detectable in the nuclei of suprabasal cell layers of WT HaCaT skin (Fig [EV5](#embr201948885-fig-0005ev){ref-type="fig"}). Compared to WT, little Notch1 signaling was observed in suprabasal layers of ΔT3 organotypic models (Fig [EV5](#embr201948885-fig-0005ev){ref-type="fig"}). Whether the observed GalNAc‐T3 glycosylation of Jagged‐1 is the direct cause of the perturbed differentiation observed in the ΔT3 skin equivalents is unclear. As an alternative explanation, loss of GalNAc‐T3 may affect the intercellular adhesion system by specific glycosylation of both protocadherin Fat 2 and desmoglein 3, which are involved in cell migration and cell--cell adhesion, respectively. Furthermore, a number of FGF and heparin binding proteins (FGFBP1, GLG1, GPC1) that modulate the availability of these growth factors have been identified as GalNAc‐T3‐specific targets and may contribute to the decreased differentiation of suprabasal keratinocytes via FGFR signaling [64](#embr201948885-bib-0064){ref-type="ref"}.

![Notch1 activity in HaCaT WT and *GALNT3* KO organotypic skin\
Immunofluorescence imaging of organotypic skin sections probed using cleaved Notch1 intracellular domain‐specific mAb (green). Nuclei were counterstained with DAPI (blue). Scale bar---20 μm.](EMBR-21-e48885-g010){#embr201948885-fig-0005ev}

Given that only a few overt phenotypes present in animal models and humans are associated with loss of GalNAc‐T function, it is in some ways surprising that loss of single GalNAc‐Ts causes such distinct phenotypes in the organotypic skin models. Loss of GalNAc‐T3 in humans seems to primarily affect phosphate homeostasis in familial tumoral calcinosis [13](#embr201948885-bib-0013){ref-type="ref"}, [24](#embr201948885-bib-0024){ref-type="ref"}, [65](#embr201948885-bib-0065){ref-type="ref"}. Different, more subtle phenotypes include a strong genome‐wide association of GalNAc‐T2 with plasma lipid profiles [21](#embr201948885-bib-0021){ref-type="ref"}, [26](#embr201948885-bib-0026){ref-type="ref"}, [66](#embr201948885-bib-0066){ref-type="ref"} or GalNAc‐T11 with congenital heart disease [19](#embr201948885-bib-0019){ref-type="ref"}. In *GALNT1* KO mice, several different issues have been observed, including a bleeding disorder, decreased leukocyte homing capacity, and impaired heart valve development [67](#embr201948885-bib-0067){ref-type="ref"}, [68](#embr201948885-bib-0068){ref-type="ref"}, [69](#embr201948885-bib-0069){ref-type="ref"}, though similar associations have not yet been discovered in humans. In all cases, the results suggest that it is only a few isoform‐specific GalNAc‐T targets that cause the observed phenotypes, and that the other isoforms and feedback mechanisms are able to compensate to a large extent. In this context, certain stress challenges are likely needed in model systems to evoke more overt phenotypes caused by the lack of a single GalNAc‐T. Thus, it is conceivable that the precancerous nature of the HaCaT cells used in the present organotypic skin model only requires minimal perturbations to provoke the overt phenotypes observed in *GALNT1* KO, *GALNT2* KO, and *GALNT3* KO tissues.

In summary, we show that O‐glycosylation is a widespread modification of proteins expressed in human epithelial cells. Furthermore, our results provide evidence that the O‐glycosylation landscape is controlled by the expressed repertoire of GalNAc‐Ts, each with specific but overlapping substrate specificities directing distinct biological functions in epithelial homeostasis. Finally, we think that the organotypic model presented here is an enabling strategy for studies of site‐specific glycosylation using precise genome editing techniques combined with sophisticated MS.

Materials and Methods {#embr201948885-sec-0009}
=====================

Tissues {#embr201948885-sec-0010}
-------

Human skin was obtained from Bodylift Surgical Clinic with approval from the Regional Ethical Committee. Sections (5 μm thick) were cut from frozen blocks and mounted on gelatin‐coated slides. Every fifth section was stained with hematoxylin--eosin and used as a reference during evaluation. Sections were fixed in cold 10% buffered neutral formalin for 15 min or cold acetone for 10 min. Immunohistochemistry (IHC) was performed as described below.

Cell culture {#embr201948885-sec-0011}
------------

The HaCaT human keratinocyte cell line was grown in DMEM supplemented with 10% FBS (HyClone) and 4 mM [l]{.smallcaps}‐glutamine. N/TERT‐1 immortalized keratinocytes (obtained from JG Rheinwalds lab, Harvard Institute of Medicine, Brigham & Women\'s Hospital) were cultured in keratinocyte serum‐free medium (K‐SFM, Gibco, Thermo Scientific) with 12.5 mg bovine pituitary extract per 500 ml medium (Gibco, Thermo Scientific), 0.2 ng/ml epidermal growth factor (EGF) (Thermo Scientific), and CaCl~2~ (Sigma) to a final Ca^2+^ concentration of 0.3 mmol/l, as described previously [70](#embr201948885-bib-0070){ref-type="ref"}. Prior to staining, cells were trypsinized and seeded on diagnostic slides, dried overnight, and fixed in ice‐cold acetone for 5 min. Alternatively, cells were cultured directly on coverslips in 24‐well plates and fixed directly in the wells with 4% PFA in PBS for 10 min, followed by permeabilization for 3 min with 0.3% Triton X‐100 in PBS at room temperature (RT), or for 5 min on ice in ice‐cold acetone/methanol (1:1). For co‐culture experiments, N/TERT‐1 keratinocytes were labeled with 5 μM CellTracker™ Orange CMTMR Dye (Thermo Scientific) for 45 min at 37°C, then trypsinized, mixed with unlabeled HaCaT keratinocytes in a 1:1 ratio (5 × 10^4^ cells of each), and seeded onto glass coverslips in complete K‐SFM. Twenty‐four hours later, the cells were shifted to low Ca^2+^ medium (50% DMEM:F12, 50% K‐SFM, supplemented with BPE and EGF) and cultured for additional 24 h before harvesting.

ZFN and CRISPR/Cas9 gene targeting {#embr201948885-sec-0012}
----------------------------------

HaCaT *GALNT1*,*GALNT2*, and *GALNT3* KOs on a WT and SimpleCell (*COSMC* KO) background were generated as described previously [71](#embr201948885-bib-0071){ref-type="ref"}. Briefly, ZFN constructs targeting *COSMC*,*GALNT1*,*GALNT2*, and *GALNT3* were custom produced (Sigma‐Aldrich) and HaCaT cells transfected with 2 μg of each GFP‐ and E2‐crimson‐tagged ZFN plasmids [72](#embr201948885-bib-0072){ref-type="ref"} via nucleofection with Amaxa Nucleofector (Lonza). Co‐transfection of non‐tagged ZFN constructs (2 μg of each) and 0.3 nmol of single‐stranded oligonucleotide (ssODN) was used to generate some of the *GALNT3* KO clones. GFP and E2‐crimson double‐positive cells were enriched by fluorescence‐activated cell sorting (FACS) and single cells cloned by limited dilution. Indels at the respective target sites were characterized by Indel Detection by Amplicon Analysis (IDAA) [73](#embr201948885-bib-0073){ref-type="ref"} and monoclonal antibody staining. Indels identified in individual cell clones were confirmed by Sanger sequencing. Additional *GALNT3* KO clones were generated by co‐transfecting 3.5 μg of each CRISPR/Cas9‐GFP and a gRNA construct targeting a different exon than the ZFN nucleases. GFP‐positive cells were enriched by FACS and single cells cloned, followed by validation with mAb staining and Sanger sequencing.

Raft culture {#embr201948885-sec-0013}
------------

Organotypic cultures were prepared as described by Dabelsteen *et al* [29](#embr201948885-bib-0029){ref-type="ref"}, [74](#embr201948885-bib-0074){ref-type="ref"}. Briefly, human fibroblasts were suspended in acid‐extracted type I collagen (4 mg/ml) and allowed to gel over a 1‐ml layer of acellular collagen in six‐well culture inserts with 3‐μm‐pore polycarbonate filters (BD Biosciences NJ, USA). Gels were allowed to contract for 4--5 days before seeding with 3 × 10^5^ HaCaT keratinocytes in serum and mitogen‐supplemented DMEM/F12 raft medium. Inserts were raised to the air--liquid interface 4 days after cell seeding, and the media changed every second day for an additional 10 days. At least three experiments were conducted at different time points with three different clones of each KO cell line, resulting in organotypic cultures with similar morphologies. The exception was the additional *GALNT3* KOs prepared with CRISPR/Cas9 targeting a different exon than the ZFN nucleases, which were only tested once. Organotypic sections were prepared and stained histochemically as described previously.

Immunofluorescence {#embr201948885-sec-0014}
------------------

Slides, coverslips, or frozen tissue sections were incubated overnight at 4°C with undiluted hybridoma supernatants or lectins: anti‐GalNAc‐T1, mouse mAb 4D8; anti‐GalNAc‐T2, mouse mAb 4C4; anti‐GalNAc‐T3, mouse mAb 2D10; anti‐Tn, mouse mAb 5F4; anti‐STn, mouse mAb 3F1 or anti‐T, biotinylated peanut agglutinin (Vector Labs, 0.5 μg/ml), ± neuraminidase treatment (*Clostridium perfringens* neuraminidase, 0.1 U/ml in 0.05 M NaAc for 1 h at 37°C); rabbit anti‐clathrin (1:50), rabbit anti‐Rab5 (1:100), rabbit anti‐Rab11 (1:100; all from CST, Endosomal Marker Antibody Sampler Kit); rabbit anti‐claudin 1 (1:200, Proteintech); mouse anti‐occludin (1:200, Proteintech); mouse anti‐JAM‐A (1:100, BIO‐RAD); mouse anti‐integrin alpha 3 (1:20 R&D Systems); mouse anti‐integrin alpha 6 (1:50, BIO‐RAD); rat anti‐integrin beta 4 (1:200, LSBio); rabbit anti‐collagen XVII α1 (1:200, Abcam); goat anti‐desmoglein 1 (1:50, Proteintech); rabbit anti‐desmocollin 2 (1:200, Proteintech); goat anti‐E‐cadherin (1:200, R&D Systems); mouse anti CD44 (1:500, R&D Systems); mouse anti‐cytokeratin 10 (1:200, DAKO, Denmark); and rabbit anti‐cleaved Notch1 ICD (1:100, CST). Bound mAbs were detected with FITC‐conjugated rabbit anti‐mouse immunoglobulins (1:100; DAKO, Denmark), rabbit F(ab')~2~ anti‐mouse IgG Alexa 488 (1:500), goat anti‐mouse IgG Alexa 488 (1:500), goat anti‐rabbit IgG Alexa 488 (1:500), donkey anti‐goat IgG Alexa 488 (1:500), goat anti‐rat IgG Alexa 488 (1:500), and streptavidin Alexa 488 (1:500) (all from Molecular Probes, Thermo Scientific, EU), or SuperBoost Tyramide kit (Thermo Fisher Scientific) according to the manufacturer\'s protocol. Slides and coverslips were mounted with ProLong Gold Antifade Reagent (with or without DAPI) (Molecular Probes, Thermo Scientific, EU). Coverslips were stained with 1 μg/ml DAPI solution for 3 min before mounting. Fluorescence micrographs were obtained on a Leica wide‐field fluorescence microscope or a Zeiss LSM710 confocal microscope. Images were assembled using Adobe Photoshop CS6, Adobe Illustrator CS6, or Zeiss ZEN Lite software.

Immunohistochemistry {#embr201948885-sec-0015}
--------------------

Paraffin‐embedded sections (3--5 μm) were used for IHC. Heat‐induced antigen retrieval was performed in Tris‐EDTA (pH 9) or citrate buffer (pH 6) before applying primary antibodies: mouse anti‐cytokeratin 10 (1:100, DAKO), rabbit anti‐cleaved Notch1 ICD (1:100, CST), mouse anti‐cyclin A (1:100, Novocastra Laboratories), and mouse anti‐Ki67 (1:100, DAKO). IHC was performed using the SuperBoost Tyramide kit (Thermo Fisher Scientific) or the Ultra Vision Quanto Detection System HRP DAB (Thermo Scientific) according to the manufacturers\' protocols. Sections were mounted with ProLong Gold Antifade Reagent with DAPI (Molecular Probes, Thermo Scientific, EU) or Tissue‐Tek Compound (Sakura).

Quantification of organotypic cultures {#embr201948885-sec-0016}
--------------------------------------

The K10‐negative area was quantified using AxioVision software. Epidermal thickness was measured on H&E images by making four vertical lines of equal distance. Five images were quantified per clone. The K10‐negative area was determined by outlining the area that was not stained positive by an anti‐K10 antibody in a total of 5 images per KO clone.

Transmission electron microscopy {#embr201948885-sec-0017}
--------------------------------

TEM was performed as described previously [29](#embr201948885-bib-0029){ref-type="ref"}. The samples were fixed with 2% (vol/vol) glutaraldehyde in 0.05 M sodium phosphate buffer (pH 7.2), rinsed three times in 0.15 M sodium cacodylate buffer (pH 7.2), and subsequently post‐fixed in 1% (wt/vol) OsO~4~ in 0.12 M sodium cacodylate buffer (pH 7.2) for 2 h. The specimens were dehydrated in a graded series of ethanol, transferred to propylene oxide, and embedded in Epon according to standard procedures. Sections (\< 80‐nm‐thick) were cut with a Reichert‐Jung Ultracut E microtome and collected on one‐hole copper grids with Formvar supporting membranes, stained with uranyl acetate and lead citrate, and subsequently examined with a Philips CM 100 transmission electron microscope (Philips, Eindhoven) operated at an accelerating voltage of 80 kV and equipped with an OSIS Veleta digital slow scan 2,000 × 2,000 CCD camera. Digital images were recorded using the ITEM software package.

RNA transcriptomic analysis {#embr201948885-sec-0018}
---------------------------

Total RNA was extracted from cells 48 h post‐confluency using the RNeasy^®^ kit (Qiagen). RNA integrity and quality were determined using Bioanalyzer instrumentation (Agilent Technologies). Analyses were performed on total RNA from three clones of each *GALNT1* KO, *GALNT2* KO, and *GALNT3* KO and two biological replicates of WT HaCaT cells. Transcriptome analysis of the extracted total RNA was performed by Beijing Genomics Institute (BGI) as reported previously [32](#embr201948885-bib-0032){ref-type="ref"}. Briefly, a library was constructed using the Illumina Truseq RNA Sample Preparation Kit and subjected to PCR amplification and quality control (QC) before undergoing next‐generation sequencing with the Illumina HiSeq 2000 System (Illumina, USA).

Bioinformatics analysis {#embr201948885-sec-0019}
-----------------------

Bioinformatics analysis was performed as described previously [32](#embr201948885-bib-0032){ref-type="ref"}. Briefly, aligned reads from the RNAseq analysis were analyzed using the DESeq [75](#embr201948885-bib-0075){ref-type="ref"} and EdgeR [76](#embr201948885-bib-0076){ref-type="ref"} packages for R and Bioconductor to identify differentially expressed transcripts. DESeq and EdgeR analyses were run using default parameters and following previously defined protocols [77](#embr201948885-bib-0077){ref-type="ref"}. Alternatively, single reads were aligned to the human genome hg19 reference sequence and analyzed using the CLC Genomics Workbench (Qiagen).

TiO~2~ enrichment of phosphopeptides {#embr201948885-sec-0020}
------------------------------------

HaCaT ΔT1, ΔT2, ΔT3 (two clones of each) and two biological replicates of WT grown in culture dishes were harvested by scraping in modified RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP‐40, 0.1% Na deoxycholate, 1 mM EDTA) supplemented with Complete Mini protease inhibitors and a mix of phosphatase inhibitors. Acetone‐precipitated proteins were reconstituted in 0.1% RapiGest (Waters) in 50 mM ammonium bicarbonate, reduced (1 mM DTT 1 h RT) and alkylated (5.5 mM CAA 1 h RT), and treated overnight with PNGase F, followed by digestion with trypsin at RT for 16 h. A total of 200 μg of each digest was labeled using the TMT‐10plex Kit (Thermo Scientific) according to the manufacturer\'s instructions, mixed in equimolar ratio, and enriched using TiO~2~ beads [78](#embr201948885-bib-0078){ref-type="ref"}. Briefly, peptides were mixed with TiO~2~ beads (0.6 mg for 100 μg peptides) in 1 M glycolic acid, 80% ACN, and 5% TFA, and vortexed vigorously for 15 min at RT. The procedure was repeated with half the amount of beads. The two batches of beads were washed with loading buffer, followed by 80% ACN, 1% TFA and 20% ACN, 0.2% TFA. The phosphopeptides were eluted with 1% NH~4~OH. Peptides before enrichment and eluted phosphopeptides were orthogonally separated using high pH fractionation and analyzed by HCD MS.

LWAC isolation of Tn and T‐O‐glycopeptides {#embr201948885-sec-0021}
------------------------------------------

LWAC isolation of Tn and T‐O‐glycopeptides was performed as described previously [27](#embr201948885-bib-0027){ref-type="ref"}, [30](#embr201948885-bib-0030){ref-type="ref"}. Briefly, proteins were reduced (5 mM DTT 45 min 60°C) and alkylated (10 mM IAA 30 min RT), digested with trypsin (Roche), and neuraminidase‐treated to remove sialic acid residues. For experiments in *COSMC* KO (SC), these steps were followed by labeling with light or medium isotopomeric dimethyl labels [42](#embr201948885-bib-0042){ref-type="ref"}. The labeled digests were mixed in a 1:1 ratio in the following sets: HaCaT^SC^ (light) and HaCaT^SC^ΔT1 (medium), HaCaT^SC^ (light) and HaCaT^SC^ΔT2 (medium), and HaCaT^SC^ (light) and HaCaT^SC^ΔT3 (medium). The mixed pairs of digests were enriched using agarose‐bound VVA LWAC and eluted with GalNAc. For experiments in WT, digests of three clones of each ΔT1, ΔT2, and ΔT3, and one WT were labeled using the TMT‐10plex Kit (Thermo Scientific) according to the manufacturer\'s instructions. Labeled digests were mixed in an equimolar ratio and enriched using Jacalin LWAC, followed by elution with D‐galactose. Isoelectric focusing was performed on VVA‐enriched glycopeptides by a 3100 OFFGEL fractionator (Agilent) using pH 3--10 strips (GE Healthcare) [79](#embr201948885-bib-0079){ref-type="ref"}. High pH fractionation was performed on TMT‐labeled Jacalin‐enriched glycopeptides, as well as peptides before enrichment. All glycopeptide samples were desalted by self‐made Stage Tips (C18 sorbent from Empore 3 M) and submitted to LC‐MS and HCD/ETD‐MS/MS.

Mass spectrometry {#embr201948885-sec-0022}
-----------------

EASY‐nLC 1000 UHPLC (Thermo Scientific) interfaced via a Nanospray Flex ion source to an LTQ‐Orbitrap Velos Pro or Orbitrap Fusion spectrometer (Thermo Scientific) was used for peptide, glycopeptide, and phosphopeptide analysis as described previously [27](#embr201948885-bib-0027){ref-type="ref"}. Data were processed using Proteome Discoverer 1.4 software (Thermo Scientific).

Intracellular pH measurements {#embr201948885-sec-0023}
-----------------------------

Intracellular pH measurements were performed as described previously [80](#embr201948885-bib-0080){ref-type="ref"}. Cells were seeded in WillCo glass‐bottom dishes (WillCoWells) and loaded with 2ʹ,7ʹ‐bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein acetoxymethyl ester (BCECF‐AM, 1.6 μM; Invitrogen) in growth medium for 30 min at 37°C prior to sample collection. Cells were washed once in isotonic Ringer solution and placed in a temperature‐controlled compartment (37°C) equipped with gas and solute perfusion. The pHi measurements were carried out using a Nikon Eclipse Ti microscope equipped with a Xenon lamp for fluorescence excitation, a 40× oil 1.4 NA objective, and EasyRatioPro imaging software (PTI). Emission was measured at 520 nm after excitation at 440 nm and 485 nm. For acid loading, cells were exposed to saline supplemented with 20 mM NH~4~Cl for 10 min. Isotonic calibration solutions were used for a 4‐point linear calibration curve to calibrate the pHi values. Fluorescence measured from the two excitation channels (440 nm and 485 nm) was corrected for the respective background fluorescence, which was assessed by measuring a cell‐free area during the experiment. The 485 nm/440 nm ratio was then calculated and the calibration data fitted to a linear function in the applied pH range, in which the experimental data were inserted and thereby converted to corrected pH values. Average pHi measurements for each time point and their standard deviations were calculated as in Ref. [80](#embr201948885-bib-0080){ref-type="ref"}.

Protein extraction and Western blotting {#embr201948885-sec-0024}
---------------------------------------

Cells grown in cell culture dishes were washed with ice‐cold PBS and lysed in modified RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP‐40, 0.1% Na deoxycholate, 1 mM EDTA) supplemented with protease and phosphatase inhibitors, followed by sonication using a sonic probe on ice. Proteins were mixed with 4× NuPAGE sample buffer and 10 mM DTT, heat denatured (95°C 5 min), and separated on Novex 4--12% gradient gel (Bis‐Tris) in 1× NuPAGE MES running buffer (Invitrogen), followed by transfer onto nitrocellulose membrane in 20% MeOH in running buffer at 320 mA overnight at 4 °C. Membranes were blocked with 5% skim milk in TBS‐T and blotted with rabbit anti‐collagen XVII α1 (1:1,000, Abcam) or mouse anti‐β actin (1:10,000, Sigma) antibodies, followed by goat anti‐rabbit Igs‐HRP or rabbit anti‐mouse Igs‐HRP (1:4,000, DAKO). Membranes were developed using Pierce ECL or ECL Plus Kits (Thermo Scientific) and visualized using the ImageQuant LAS4000 system. Protein bands were quantified using ImageJ software.

LDL uptake {#embr201948885-sec-0025}
----------

Cells grown on coverslips were cultured in media supplemented with 10% lipoprotein‐depleted serum (Sigma‐Aldrich) for 24 h, followed by pulsing with 70 nM Lysotracker Red DND‐99 (Thermo Fisher Scientific) (−1 h) and 14 μg/ml LDL‐pHrodo (Thermo Fisher Scientific) (0 h). Coverslips were fixed with 4% PFA for 5 min at 1 h, 1.5 h, and 2.5 h and imaged using confocal microscopy.

Cell--matrix adhesion assay {#embr201948885-sec-0026}
---------------------------

Cell to ECM adhesion was tested using the CytoSelect™ 48‐well Cell Adhesion Assay (Cell Biolabs) according to the manufacturer\'s protocol. Briefly, the cells were trypsinized and allowed to adhere for 1 hour at 37°C. The unbound cells were washed off, stained, lysed, and quantified using a plate reader at a wavelength of 560 nm. The experiment was set up in duplicate for each cell line. The results are representative of three independent experiments.
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